Evidence-based therapy for cutaneous sarcoidosis.

Area of Science:

• Dermatology
• Immunology
• Rheumatology

Background:

• Cutaneous sarcoidosis management relies heavily on anecdotal evidence rather than robust clinical trials.
• Established treatments include corticosteroids, antimalarials, and methotrexate, often used sequentially.

Purpose of the Study:

• To review current and emerging treatment strategies for cutaneous sarcoidosis.
• To highlight the limitations of existing therapies and the potential of novel approaches.

Main Methods:

• Review of existing literature on cutaneous sarcoidosis treatments.
• Discussion of standard therapies (corticosteroids, antimalarials, methotrexate) and their limitations.
• Exploration of newer treatment modalities, including biologics (TNF-alpha inhibitors), isotretinoin, thalidomide, and laser therapy.

Main Results:

• Standard therapies, while widely accepted, often yield incomplete responses or adverse events.
• Tumor necrosis factor-alpha inhibitors (infliximab, adalimumab) show promising early results for recalcitrant cases.
• Other agents like doxycycline, minocycline, and laser therapy offer potential alternative or adjunctive treatments.

Conclusions:

• There is a need for more evidence-based guidelines in managing cutaneous sarcoidosis.
• Novel therapies, particularly biologics, represent a significant advancement for treatment-resistant disease.
• A stepwise approach incorporating both established and emerging treatments is crucial for optimal patient outcomes.